IONIS PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Private, Subsidiary
- Established
- 1989-01-01
- Employees
- 927
- Market Cap
- -
- Website
- http://www.ionis.fr
Ionis Announces Olezarsen New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed
Ionis Pharmaceuticals' olezarsen NDA accepted for Priority Review by FDA for FCS treatment, with action date set for December 19, 2024. Phase 3 sHTG program enrollment completed. Olezarsen targets apoC-III to lower triglyceride levels, reducing acute pancreatitis risk in FCS and sHTG patients.
© Copyright 2024. All Rights Reserved by MedPath